Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statements Detail (Tables)

v3.4.0.3
Condensed Consolidated Financial Statements Detail (Tables)
3 Months Ended
Mar. 31, 2016
Condensed Consolidated Financial Statements Detail [Abstract]  
Accrued and other liabilities

Accrued and other liabilities consisted of the following (in thousands):

 

 

 

March 31,

2016

 

 

December 31,

2015

 

Accrued payroll and other benefits

 

$

1,573

 

 

$

2,156

 

Deferred rent

 

 

724

 

 

 

608

 

Accrued clinical trial costs

 

 

517

 

 

 

406

 

Accrued legal and accounting fees

 

 

511

 

 

 

517

 

Accrued incentive compensation

 

 

243

 

 

 

2,609

 

Accrued restructuring costs

 

 

138

 

 

 

459

 

Other

 

 

681

 

 

 

270

 

Total

 

$

4,387

 

 

$

7,025

 

 

Outstanding securities considered anti-dilutive

 

The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share of common stock (in thousands):

 

 

 

Three Months Ended March 31,

 

 

 

2016

 

 

2015

 

Common stock options and RSUs

 

 

10,704

 

 

 

8,756

 

Warrants for common stock

 

 

18,230

 

 

 

20,690

 

Total

 

 

28,934

 

 

 

29,446